NYSE:NVTA Invitae (NVTA) Stock Price, News & Analysis $0.0003 0.00 (0.00%) (As of 08/9/2024) Add Compare Share Share Today's Range$0.0003▼$0.000350-Day Range N/A52-Week Range$0.02▼$0.02Volume75 shsAverage Volume23.72 million shsMarket Capitalization$80,103.00P/E RatioN/ADividend YieldN/APrice Target$0.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSustainabilityTrends Get Invitae alerts: Email Address Invitae MarketRank™ Stock AnalysisAnalyst RatingSell1.00 Rating ScoreUpside/Downside166,566.7% Upside$0.50 Price TargetShort InterestN/ADividend StrengthN/ASustainability-1.13Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.05) to ($0.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.61 out of 5 stars 2.5 Analyst's Opinion Consensus RatingInvitae has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageInvitae has received no research coverage in the past 90 days.Read more about Invitae's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for NVTA. Previous Next 0.0 Dividend Strength Dividend YieldInvitae does not currently pay a dividend.Dividend GrowthInvitae does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInvitae has received a 71.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private genetic testing services" and "Diagnostic test kits" products. See details.Environmental SustainabilityThe Environmental Impact score for Invitae is -1.13. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows1 people have added Invitae to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Invitae insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.74% of the stock of Invitae is held by insiders.Percentage Held by Institutions61.28% of the stock of Invitae is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Invitae's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Invitae are expected to grow in the coming year, from ($1.05) to ($0.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Invitae is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Invitae is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInvitae has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsNASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...Click here to learn more >>> About Invitae Stock (NYSE:NVTA)Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.Read More NVTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVTA Stock News HeadlinesAugust 29, 2024 | americanbankingnews.comInvitae (NYSE:NVTA) Earns Hold Rating from Analysts at StockNews.comJuly 22, 2024 | finance.yahoo.comInvitae Launches Unlock™ Behind the Seizure® Program for Pediatric Epilepsy PatientsSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...May 7, 2024 | bizjournals.comInvitae's $239 million sale to Labcorp approved by Bankruptcy CourtApril 28, 2024 | msn.comLabcorp to acquire Invitae in strategic dealApril 26, 2024 | uk.investing.comLabcorp to acquire Invitae assets for $239 millionApril 26, 2024 | bizjournals.comLabcorp wins $239M bid for bankrupt InvitaeApril 25, 2024 | msn.comLabcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae DealSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...April 25, 2024 | finanznachrichten.deInvitae Corporation: Invitae Enters into Agreement with Labcorp for Sale of BusinessApril 25, 2024 | marketwatch.comLabcorp to Buy Assets of Bankrupt Invitae for $239MApril 24, 2024 | reuters.comClinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mlnApril 24, 2024 | finance.yahoo.comInvitae Enters into Agreement with Labcorp for Sale of BusinessApril 24, 2024 | prnewswire.comLabcorp Announces Winning Bid for Select Assets of InvitaeApril 22, 2024 | tmcnet.comInvitae Publishes its Environmental, Social and Governance (ESG) ReportApril 11, 2024 | finance.yahoo.comInvitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain SignificanceApril 11, 2024 | prnewswire.comInvitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain SignificanceApril 2, 2024 | bizjournals.comPioneering cancer test company wants court to slow potential sale of Invitae's cancer-monitoring productsSee More Headlines Receive NVTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2023Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNYSE:NVTA CUSIPN/A CIK1501134 Webwww.invitae.com Phone(628) 213-3369FaxN/AEmployees1,700Year FoundedN/APrice Target and Rating Average Stock Price Target$0.50 High Stock Price Target$0.50 Low Stock Price Target$0.50 Potential Upside/Downside+166,566.7%Consensus RatingSell Rating Score (0-4)1.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($5.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,106,290,000.00 Net Margins-299.14% Pretax Margin-301.93% Return on Equity-6,100.71% Return on Assets-19.68% Debt Debt-to-Equity RatioN/A Current Ratio2.39 Quick Ratio2.25 Sales & Book Value Annual Sales$481.58 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.42 per share Price / Book0.00Miscellaneous Outstanding Shares267,010,000Free Float284,373,000Market Cap$80,103.00 OptionableOptionable Beta1.59 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Randal W. Scott Ph.D. (Age 66)Co-Founder & Chairman of the Board Comp: $50kMr. Kenneth D. Knight (Age 63)President, CEO & Director Comp: $1.4MMr. Thomas R. Brida (Age 53)General Counsel, Chief Compliance Officer & Secretary Comp: $776.72kMs. Ana J. Schrank (Age 58)Chief Accounting Officer & CFO Dr. David B. Sholehvar M.D. (Age 56)Chief Operating Officer Ms. Hoki Luk (Age 48)Head of Investor Relations and Capital Markets Ms. Shelly D. Guyer (Age 64)Chief Sustainability Officer Comp: $430.44kMs. Desarie FrenchChief Talent OfficerDr. W. Michael Korn M.D.Chief Medical OfficerMr. Robert GuigleyChief Commercial OfficerMore ExecutivesKey CompetitorsLaboratory Co. of AmericaNYSE:LHQuest DiagnosticsNYSE:DGXNateraNASDAQ:NTRAExact SciencesNASDAQ:EXASRadNetNASDAQ:RDNTView All Competitors NVTA Stock Analysis - Frequently Asked Questions How have NVTA shares performed this year? Invitae's stock was trading at $0.6268 at the start of the year. Since then, NVTA stock has decreased by 100.0% and is now trading at $0.0003. View the best growth stocks for 2024 here. How were Invitae's earnings last quarter? Invitae Co. (NYSE:NVTA) released its quarterly earnings data on Tuesday, May, 9th. The medical research company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.04. The firm's revenue was down 5.1% compared to the same quarter last year. What is Sean George's approval rating as Invitae's CEO? 59 employees have rated Invitae Chief Executive Officer Sean George on Glassdoor.com. Sean George has an approval rating of 87% among the company's employees. When did Invitae IPO? Invitae (NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers. How do I buy shares of Invitae? Shares of NVTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Invitae own? Based on aggregate information from My MarketBeat watchlists, some other companies that Invitae investors own include NVIDIA (NVDA), Block (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD) and Shopify (SHOP). This page (NYSE:NVTA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredHere’s A Painful Truth and 100% Fact About The Stocks You’re HoldingCharles Payne here, and I want to let you in on an uncomfortable truth that long term investors and retirees n...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invitae Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invitae With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
